Evidence map›Paper›PMID 42540647›Full record

ArticleJournal of the Royal Statistical Society. Series C, Applied statistics2026

Modeling Cure from Cancer Accounting for Inevitable Mortality.

Suvra Pal, Suchitrita Sarkar Rathmann, Qi Jiang, Jiehuan Sun, Debajyoti Sinha, Sanjib Basu

Abstract read
In one paragraph

Article in Journal of the Royal Statistical Society. Series C, Applied statistics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Suvra PalDepartment of Mathematics, University of Texas at Arlington, Arlington, TX 76019, United States.
Suchitrita Sarkar RathmannMerck & Co., Inc., Rahway, NJ, USA.
Qi JiangAbbVie Inc., North Chicago, Illinois, USA.
Jiehuan SunDivision of Epidemiology and Biostatistics, University of Illinois Chicago.
Debajyoti SinhaDepartment of Statistics, University of Florida.
Sanjib BasuDivision of Epidemiology and Biostatistics, University of Illinois Chicago.

Funding

Machine Learning-Based Predictive Models for Disease Cure and Computationally Efficient Methods in High-Dimensional SettingsR35GM156859 · NIGMS · UNIVERSITY OF TEXAS ARLINGTON · PI SUVRA PAL · 2025 to 2026
$643k
Using Machine Learning to Improve the Predictive Accuracy of Disease CureR15GM150091 · NIGMS · UNIVERSITY OF TEXAS ARLINGTON · PI PAL, SUVRA · 2023 to 2023
$452k
NIGMS NIH HHS R15 GM150091NIGMS NIH HHS R35 GM156859
6 · The paper itself

Abstract

Cancer remains the second most prevalent cause of death in the United States, claiming 605,213 lives in 2021, surpassing COVID-19 deaths. The cancer mortality rate continued to decline between 2019 and 2020, dropping by 1.5%, marking a significant 33% decrease since 1991. This ongoing improvement primarily mirrors advances in treatment, allowing patients to achieve clinical remission and recovery. Now, a cancer patient is simultaneously exposed to the risk of primary cancer as well as other risks, such as other cancer(s) or other diseases, leading to a competing risks scenario. Analysis of survival data under competing risks and the presence of cured patients have been extensively studied individually, but there is limited work in the current literature that models the possibility of cure from one risk in the presence of competing risks. Moreover, such a model should allow for the possibility of cure from the cause-specific risk of the primary cancer; however, the overall survival probability should eventually approach zero, thereby incorporating the prevalent belief of eventual failure with certainty. We propose a novel unified competing risks cure model, based on the cause-specific hazard approach, that satisfies the aforementioned desired properties. The conditions required to establish model identifiability are studied in detail. To find the maximum likelihood estimates of the model parameters, a computationally efficient expectation maximization algorithm is developed. An extensive simulation study is carried out to demonstrate the performance of the proposed model and estimation method under different parameter settings and in the presence of multiple competing risks. Finally, an application is illustrated using breast cancer data from the SEER cancer database.

Indexed as

Breast cancerCause-specific hazardCompeting risksCure rateEM algorithmIdentifiability

Identifiers

PMID42540647
PMCPMC13426226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.